retatrutide effects clinical trial retatrutide (RETA) is one of the most promising investigational peptides in obesity research—but one important question deserves more attention: Can it affect birth control? Current evidence shows that GLP-1 receptor agonists slow Triple hormone receptor agonist retatrutide
Description
One of those dual agonists, tirzepatide (Mounjaro/Zepbound, Eli Lilly), was associated with a mean 14.7% weight loss for adults with overweight or obesity and type 2 diabetes in the SURMOUNT-2 trial compared with a 3.2% weight loss with placebo

Adults with a BMI 30 or 27 with weight-related conditions
Liraglutide, as an individual agent, significantly improved LVEF in individuals with AMI (Class IV

Drugs (2024)

How do I get started with GLP-1 medications

